Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

ABCD1 translation-initiator mutation demonstrates genotype-phenotype correlation for AMN.

O'Neill GN, Aoki M, Brown RH Jr.

Neurology. 2001 Dec 11;57(11):1956-62.

PMID:
11739809
2.

ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations.

Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, Cutting GR, Wanders RJ, Moser HW.

Hum Mutat. 2001 Dec;18(6):499-515. Review.

PMID:
11748843
3.

[Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].

Morita M.

Yakugaku Zasshi. 2007 Jul;127(7):1059-64. Review. Japanese.

4.
5.

[X-linked adrenoleukodystrophy].

Aubourg P.

Ann Endocrinol (Paris). 2007 Dec;68(6):403-11. Epub 2007 May 29. Review. French.

PMID:
17532287
6.

Biochemical aspects of X-linked adrenoleukodystrophy.

Kemp S, Wanders R.

Brain Pathol. 2010 Jul;20(4):831-7. doi: 10.1111/j.1750-3639.2010.00391.x. Review.

PMID:
20626744
7.

X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment.

Kemp S, Wanders RJ.

Mol Genet Metab. 2007 Mar;90(3):268-76. Epub 2006 Nov 7. Review.

PMID:
17092750
8.

General aspects and neuropathology of X-linked adrenoleukodystrophy.

Ferrer I, Aubourg P, Pujol A.

Brain Pathol. 2010 Jul;20(4):817-30. doi: 10.1111/j.1750-3639.2010.00390.x. Review.

PMID:
20626743
9.

Adrenoleukodystrophy.

Cappa M, Bizzarri C, Vollono C, Petroni A, Banni S.

Endocr Dev. 2011;20:149-60. doi: 10.1159/000321236. Epub 2010 Dec 16. Review.

PMID:
21164268
10.

Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy.

Moser HW.

J Neuropathol Exp Neurol. 1995 Sep;54(5):740-5. Review.

PMID:
7666063
11.

X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.

Kemp S, Berger J, Aubourg P.

Biochim Biophys Acta. 2012 Sep;1822(9):1465-74. doi: 10.1016/j.bbadis.2012.03.012. Epub 2012 Mar 28. Review.

12.

Cerebral inflammation in X-linked adrenoleukodystrophy.

McGuinness MC, Smith KD.

Arch Immunol Ther Exp (Warsz). 1999;47(5):281-7. Review.

PMID:
10604233
13.

Therapy of X-linked adrenoleukodystrophy.

Semmler A, Köhler W, Jung HH, Weller M, Linnebank M.

Expert Rev Neurother. 2008 Sep;8(9):1367-79. doi: 10.1586/14737175.8.9.1367. Review.

14.

DNA diagnosis of X-linked adrenoleukodystrophy.

Seneca S, Lissens W.

J Inherit Metab Dis. 1995;18 Suppl 1:34-44. Review.

PMID:
9053554
15.

ABC subfamily D proteins and very long chain fatty acid metabolism as novel targets in adrenoleukodystrophy.

Morita M, Shimozawa N, Kashiwayama Y, Suzuki Y, Imanaka T.

Curr Drug Targets. 2011 May;12(5):694-706. Review.

PMID:
21039332
16.

Adrenoleukodystrophy gene: unexpected homology to a protein involved in peroxisome biogenesis.

Aubourg P, Mosser J, Douar AM, Sarde CO, Lopez J, Mandel JL.

Biochimie. 1993;75(3-4):293-302. Review.

PMID:
8507690
17.

Mutational analysis of X-linked adrenoleukodystrophy gene.

Takano H, Koike R, Onodera O, Tsuji S.

Cell Biochem Biophys. 2000;32 Spring:177-85. Review.

PMID:
11330045
18.

Mutations in the adrenoleukodystrophy gene.

Dodd A, Rowland SA, Hawkes SL, Kennedy MA, Love DR.

Hum Mutat. 1997;9(6):500-11. Review.

PMID:
9195223
19.

X-linked adrenoleukodystrophy: diagnostic and follow-up system in Japan.

Shimozawa N, Honda A, Kajiwara N, Kozawa S, Nagase T, Takemoto Y, Suzuki Y.

J Hum Genet. 2011 Feb;56(2):106-9. doi: 10.1038/jhg.2010.139. Epub 2010 Nov 11. Review.

PMID:
21068741
20.

X-linked adrenoleukodystrophy.

Moser HW, Mahmood A, Raymond GV.

Nat Clin Pract Neurol. 2007 Mar;3(3):140-51. Review.

PMID:
17342190

Supplemental Content

Support Center